NBIX: Neurocrine Biosciences, Inc. - Summary | Jitta

Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Price
$113.68
Loss Chance
47.7%
5.88JITTA SCORE
254.62%Over Jitta Line
Jitta Ranking
86 / 1,156
1,062 / 5,063
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (58)
Recent Business Performance (86)
Financial Strength (82)
Return to Shareholders (44)
Competitive Advantage (78)
Jitta Signs
Recent Business PerformanceEarning Growth Last Quarter (YoY)
Debt LevelLow Long Term Debt
CapExVery Low
Interest Coverage RatioGood
Cash Conversion CycleLess than 60 days
Revenue and EarningEarning loss detected in 2017
Operating MarginInconsistent
Key Stats
Jitta Score
Jitta Line
5.88
254.62%
1.29
147.43%
2.00
168.87%
Biotechnology
5.58
213.65%
6.29
22.35%
6.75
36.98%
COMPANY DESCRIPTION
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company’s portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company’s commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson’s disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company’s products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.